{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2FRefractory+Multiple+Myeloma+%28RRMM%29&page=3", "query": { "condition": "Relapsed/Refractory Multiple Myeloma (RRMM)", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 84, "total_pages": 9, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2FRefractory+Multiple+Myeloma+%28RRMM%29&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2FRefractory+Multiple+Myeloma+%28RRMM%29&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-09T01:33:43.839Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03848845", "title": "Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "belantamab mafodotin", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2019-03-14", "completion_date": "2023-06-14", "has_results": true, "last_update_posted_date": "2024-04-09", "last_synced_at": "2026-10-09T01:33:43.839Z", "location_count": 4, "location_summary": "Atlanta, Georgia • Indianapolis, Indiana • Charlotte, North Carolina + 1 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT03848845" }, { "nct_id": "NCT04458831", "title": "A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Plasma Cell Myeloma" ], "interventions": [ { "name": "isatuximab SAR650984", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 583, "start_date": "2020-08-13", "completion_date": "2026-02-23", "has_results": false, "last_update_posted_date": "2026-07-29", "last_synced_at": "2026-10-09T01:33:43.839Z", "location_count": 24, "location_summary": "Little Rock, Arkansas • Fullerton, California • San Francisco, California + 21 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Fullerton", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04458831" }, { "nct_id": "NCT03481556", "title": "Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Melphalan flufenamide (Melflufen)", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oncopeptides AB", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": "2018-04-12", "completion_date": "2022-02-02", "has_results": true, "last_update_posted_date": "2022-12-19", "last_synced_at": "2026-10-09T01:33:43.839Z", "location_count": 2, "location_summary": "Boston, Massachusetts • Columbus, Ohio", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03481556" }, { "nct_id": "NCT03000452", "title": "A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "DARATUMUMAB", "type": "DRUG" }, { "name": "DURVALUMAB", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2017-03-14", "completion_date": "2017-12-04", "has_results": true, "last_update_posted_date": "2018-10-16", "last_synced_at": "2026-10-09T01:33:43.839Z", "location_count": 12, "location_summary": "Duarte, California • Southington, Connecticut • Fort Wayne, Indiana + 8 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Southington", "state": "Connecticut" }, { "city": "Fort Wayne", "state": "Indiana" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Westwood", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03000452" }, { "nct_id": "NCT03110562", "title": "Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Selinexor", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Karyopharm Therapeutics Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 402, "start_date": "2017-05-24", "completion_date": "2022-05-12", "has_results": true, "last_update_posted_date": "2024-08-21", "last_synced_at": "2026-10-09T01:33:43.839Z", "location_count": 20, "location_summary": "Plantation, Florida • Atlanta, Georgia • Honolulu, Hawaii + 16 more", "locations": [ { "city": "Plantation", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Honolulu", "state": "Hawaii" }, { "city": "Ames", "state": "Iowa" }, { "city": "Topeka", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03110562" }, { "nct_id": "NCT07280013", "title": "A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma (MM)" ], "interventions": [ { "name": "Cemsidomide", "type": "DRUG" }, { "name": "Elranatamab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "C4 Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2026-02-06", "completion_date": "2029-06", "has_results": false, "last_update_posted_date": "2026-08-12", "last_synced_at": "2026-10-09T01:33:43.839Z", "location_count": 20, "location_summary": "Gilbert, Arizona • Sacramento, California • Santa Monica, California + 17 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Sacramento", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07280013" }, { "nct_id": "NCT02649790", "title": "Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Relapsed/Refractory Multiple Myeloma (RRMM)", "Metastatic Colorectal Cancer (mCRC)", "Metastatic Castration-Resistant Prostate Cancer (mCRPC)", "Higher-Risk Myelodysplastic Syndrome (HR-MDS)", "Acute Myeloid Leukemia (AML)", "Newly Diagnosed Intermediate/High-Risk MDS" ], "interventions": [ { "name": "KPT-8602", "type": "DRUG" }, { "name": "ASTX727", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Karyopharm Therapeutics Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 277, "start_date": "2016-01", "completion_date": "2024-12-23", "has_results": false, "last_update_posted_date": "2025-03-19", "last_synced_at": "2026-10-09T01:33:43.839Z", "location_count": 26, "location_summary": "Los Angeles, California • Pasadena, California • Aurora, Colorado + 23 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Littleton", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02649790" }, { "nct_id": "NCT05462639", "title": "Elranatamab Expanded Access Protocol in Adults With Relapsed/Refractory Multiple Myeloma", "overall_status": "NO_LONGER_AVAILABLE", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Elranatamab (PF-06863135)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2024-08-09", "last_synced_at": "2026-10-09T01:33:43.839Z", "location_count": 33, "location_summary": "Los Angeles, California • Orange, California • Miami, Florida + 16 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05462639" }, { "nct_id": "NCT06352866", "title": "Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma", "Cytokine Release Syndrome", "Refractory Multiple Myeloma", "Immune Effector Cell Associated Neurotoxicity Syndrome" ], "interventions": [ { "name": "Siltuximab", "type": "DRUG" }, { "name": "Teclistamab(FDA-approved)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jack Khouri, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2025-01-01", "completion_date": "2025-12-01", "has_results": false, "last_update_posted_date": "2025-03-03", "last_synced_at": "2026-10-09T01:33:43.839Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06352866" }, { "nct_id": "NCT03110822", "title": "A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Ruxolitinib Oral Tablet [Jakafi]", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oncotherapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 134, "start_date": "2017-02-01", "completion_date": "2027-02", "has_results": false, "last_update_posted_date": "2023-11-01", "last_synced_at": "2026-10-09T01:33:43.839Z", "location_count": 13, "location_summary": "Alhambra, California • Bakersfield, California • Encinitas, California + 9 more", "locations": [ { "city": "Alhambra", "state": "California" }, { "city": "Bakersfield", "state": "California" }, { "city": "Encinitas", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Fountain Valley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03110822" } ] }